When you're hunting for attractive stocks to buy, it's often helpful to make comparisons between companies in the same line of work to tease out the leaders from the laggards. On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. But while the two companies are splitting the profits from sales of the jab, their share prices are radically diverging.

Though Pfizer's shares are up 7.6% in the last 12 months, handily outperforming the market's decline of nearly 4%, BioNTech's stock is down by a stomach-wrenching 55%. And that massive performance gap between the pair is likely to continue for at least a few quarters -- here's why.

Some investors may be wondering why BioNTech's and Pfizer's stocks can behave so differently when they both contractually profit the same amount from their commercializing Comirnaty. The answer is that for Pfizer, coronavirus vaccines accounted for only $8.8 billion of its $27.8 billion in second-quarter revenue. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.

Continue reading

Source Fool.com